June 15 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX
* Seeks trading halt pending review status of its current clinical trial in allergic rhinitis Source text for Eikon: Further company coverage: PAR.AX
June 15 (Reuters) - Paradigm Biopharmaceuticals Ltd PAR.AX
* Seeks trading halt pending review status of its current clinical trial in allergic rhinitis Source text for Eikon: Further company coverage: PAR.AX